The patent expiration for Semaglutide, the active ingredient in Ozempic, is anticipated in March 2026, potentially reducing treatment costs by 50% to ₹4,000-₹6,000 per month in India. This development is projected to create a ₹10,000 crore market opportunity within India's pharmaceutical sector. Major Indian pharmaceutical companies, including Sun Pharma, Lupin, Torrent, and Intas, are well-positioned to capitalize on this due to their existing portfolios in diabetes and metabolic drugs.